In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sawai Aims To Overcome US Slide

Japanese Firm Still Optimistic On Meeting Full-Year Forecasts

Executive Summary

Sawai says it is still on track to meet its financial targets for the current financial year, despite a slump in US sales and profits.

You may also be interested in...

Sawai Sets Upsher-Smith $50m+ Target For Former Reddy’s Brands

Sawai believes the Zembrace and Tosymra sumatriptan brands acquired by its US operation Upsher-Smith could within the next three years bring in more than $50m in annual sales.

Sawai Eyes Global Position Helped By Growth In Japan And Upsher-Smith – But No Biosimilars

In an exclusive interview, the president of Japan’s largest generics company relates his strategy for success, including internal expertise in intellectual property challenges and staying away from biosimilars. US acquisition Upsher-Smith will meanwhile provide the foundation for overseas growth.

Adalvo Partners With AmbioPharm For Several Complex Products

Alvogen’s newly created B2B unit, Adalvo, has partnered with AmbioPharm for the co-development and licensing for the commercialization of several complex pharmaceutical products, including difficult-to-make peptides, in key global markets.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts